Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel
Sabino De Placido, Grazia Arpino(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antônio Bernardo(Fondazione Salvatore Maugeri), Teresa Gamucci, Claudia De Angelis(University of Naples Federico II), Alessandra Fabi(Agostino Gemelli University Polyclinic), Irene De Santo(University of Molise), Mario Giuliano(Regione Campania), Lucia Del Mastro(Ospedale Policlinico San Martino), Dario Bruzzese(University of Naples Federico II), EE Baldini(Istituti Clinici Scientifici Maugeri), Rossella Lauria, Vincenzo Montesarchio(CTO Hospital), Salvatore Russo(Imperial College Healthcare NHS Trust), Pietro De Placido(University of Naples Federico II)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724